Steroid but not biological therapy elevates the risk of venous thromboembolic events in inflammatory bowel disease a meta-analysis /
Background and aim: Inflammatory bowel disease [IBD] is associated with 1.5- to 3-fold increased risk of venous thromboembolic events [VTE]. The aim of this study was to determine the risk of VTE in IBD as a complication of systemic corticosteroids and anti-tumor necrosis factor alpha [TNFalpha] the...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2018
|
| Sorozat: | JOURNAL OF CROHNS & COLITIS
12 No. 4 |
| Tárgyszavak: | |
| doi: | 10.1093/ecco-jcc/jjx162 |
| mtmt: | 3302386 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/13202 |
| LEADER | 03075nab a2200385 i 4500 | ||
|---|---|---|---|
| 001 | publ13202 | ||
| 005 | 20220927123926.0 | ||
| 008 | 180413s2018 hu o 0|| angol d | ||
| 022 | |a 1873-9946 | ||
| 024 | 7 | |a 10.1093/ecco-jcc/jjx162 |2 doi | |
| 024 | 7 | |a 3302386 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a angol | ||
| 100 | 1 | |a Sarlós Patrícia | |
| 245 | 1 | 0 | |a Steroid but not biological therapy elevates the risk of venous thromboembolic events in inflammatory bowel disease |h [elektronikus dokumentum] : |b a meta-analysis / |c Sarlós Patrícia |
| 260 | |c 2018 | ||
| 300 | |a 489-498 | ||
| 490 | 0 | |a JOURNAL OF CROHNS & COLITIS |v 12 No. 4 | |
| 520 | 3 | |a Background and aim: Inflammatory bowel disease [IBD] is associated with 1.5- to 3-fold increased risk of venous thromboembolic events [VTE]. The aim of this study was to determine the risk of VTE in IBD as a complication of systemic corticosteroids and anti-tumor necrosis factor alpha [TNFalpha] therapies. Methods: A systematic review and meta-analysis was conducted, which conforms to the Preferred Reporting Items for Systematic Reviews and Meta-analyses [PRISMA] statement. PubMed, EMBASE, Cochrane Library, and Web of Science were searched for English-language studies published from inception inclusive 15 April 2017. The population-intervention-comparison-outcome [PICO] format and statistically the random-effects and fixed-effect models were used to compare VTE risk during steroid and anti-TNFalpha treatment. Quality of the included studies was assessed using the Newcastle-Ottawa scale. PROSPERO registration number is 42017070084. Results: We identified 817 records, of which eight observational studies, involving 58,518 IBD patients, were eligible for quantitative synthesis. In total, 3,260 thromboembolic events occurred. Systemic corticosteroids were associated with a significantly higher rate of VTE complication in IBD patients as compared to IBD patients without steroid medication [OR: 2.202; 95% CI: 1.698-2.856, p < 0.001]. In contrast, treatment with anti-TNFalpha agents resulted in a 5-fold decreased risk of VTE compared to steroid medication [OR: 0.267; 95% CI: 0.106-0.674, p = 0.005]. Conclusion: VTE risk should be carefully assessed and considered when deciding between anti-TNFalpha and steroids in the management of severe flare-ups. Thromboprophylaxis guidelines should be followed, no matter the therapy choice. | |
| 650 | 4 | |a Klinikai orvostan | |
| 700 | 0 | 1 | |a Szemes Kata |e aut |
| 700 | 0 | 1 | |a Hegyi Péter |e aut |
| 700 | 0 | 1 | |a Garami András |e aut |
| 700 | 0 | 1 | |a Szabó Imre |e aut |
| 700 | 0 | 1 | |a Illés Anita |e aut |
| 700 | 0 | 2 | |a Szekeres-Solymár Margit |e aut |
| 700 | 0 | 2 | |a Rittmann-né Pétervári Erika |e aut |
| 700 | 0 | 2 | |a Vincze Áron |e aut |
| 700 | 0 | 2 | |a Pár Gabriella |e aut |
| 700 | 0 | 2 | |a Bajor Judit |e aut |
| 700 | 0 | 2 | |a Czimmer József |e aut |
| 700 | 0 | 2 | |a Huszár Orsolya |e aut |
| 700 | 0 | 2 | |a Varjú Péter |e aut |
| 700 | 0 | 2 | |a Borbásné Farkas Kornélia |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/13202/1/cikk_2_sarlos_2018_u.pdf |z Dokumentum-elérés |